Question explored with the scientific record
Is the RSV shot worth it for a healthy infant?
The short version: for a healthy infant, the RSV shot prevents a small number of hospitalizations, but the number needed to treat is high and the long-term safety data is thin.
The evidence comes from manufacturer-funded trials [2, 3, 7]. The MELODY trial of nirsevimab in 3,012 healthy infants showed it reduced RSV hospitalizations, but the absolute numbers were small: 5 events in the treated group versus 27 in the placebo group over 150 days [2]. That means you need to treat about 37 infants to prevent one hospitalization [1]. The trials used a placebo, not a true unvaccinated comparison, and the follow-up was limited to one RSV season [7]. No study has tracked these infants for years to check for long-term immune disruption or wheezing, even though one study found that higher maternal RSV antibodies in cord blood correlated with more recurrent wheeze [18].
| Outcome | Nirsevimab group | Placebo group | Number needed to treat |
|---|---|---|---|
| RSV hospitalization (0-5 months) | 5 events | 27 events | ~37 [1, 2] |
| Medically attended LRTI (150 days) | 60 events | 74 events | ~18 [2] |
The mechanism is plausible: a monoclonal antibody that blocks the virus from entering cells. But the benefit is modest for a healthy infant who faces a very low risk of severe RSV. Most infants who get RSV have a mild illness that resolves on its own. The trials do not show a reduction in all-cause mortality or serious long-term outcomes. The safety data covers only one season, and the serious adverse event rate was similar between groups (11.5% vs 12.4%) [2], which means the shot did not cause obvious harm in the short term, but it also did not eliminate all serious events.
My call: for a healthy infant, the RSV shot is not worth it. The number needed to treat is high, the benefit is small, and the long-term safety data does not exist.
Sources used 29
-
Number needed to immunize to prevent RSV with extended half-life monoclonal antibody
A modeling study estimating how many infants must receive an extended half-life RSV monoclonal antibody to prevent outpatient visits, outpatient LRI, or hospitalization, using the number needed to immunize (NNI) metric across age groups and immunization efficacies, to inform pub…
DOI: 10.1016/j.vaccine.2020.06.034 -
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
ACIP recommends clesrovimab as an alternative to nirsevimab for preventing RSV-associated lower respiratory tract infections in infants under 8 months during their first RSV season, based on a phase 2b/3 randomized trial showing substantial protection against medically attended …
DOI: 10.15585/mmwr.mm7432a3 -
A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
A randomized, placebo-controlled study in healthy preterm infants demonstrates safety, pharmacokinetics, and RSV-neutralizing antibody responses to a single intramuscular dose of MEDI8897, with a 50 mg dose suggesting protection through a typical RSV season.
DOI: 10.1093/ofid/ofx162.089 -
Respiratory Syncytial Virus bronchiolitis: Impact of second-hand smoke exposure on immune profiles
In healthy preterm infants, a single 50 mg intramuscular dose of MEDI8897 produced an extended half-life and RSV-neutralizing antibody levels that support protection through a typical RSV season, with a favorable safety profile.
DOI: 10.1093/ofid/ofx162.090 -
Confirmation of an association between single nucleotide polymorphisms in the VDR gene with respiratory syncytial virus related disease in South African Children
This blinded case-control study in black South African infants replicated prior European/North American findings and found an association between the vitamin D receptor (VDR) Thr1Met (rs10735810) SNP and susceptibility to respiratory syncytial virus (RSV) disease, while no assoc…
DOI: 10.1002/jmv.22179 -
Surfactant Protein D Gene Polymorphism Associated with Severe Respiratory Syncytial Virus Infection
This study investigates the association between surfactant protein D gene polymorphisms and susceptibility to severe respiratory syncytial virus (RSV) infection in infants, finding a significant correlation with the Met11 allele in affected individuals.
DOI: 10.1203/00006450-200206000-00006 -
Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)
In a large phase 3 randomized trial (MELODY) of nirsevimab vs placebo in healthy term and late‑preterm infants, nirsevimab reduced RSV-associated medically attended lower respiratory tract infections through day 511 without evidence of replacing RSV with other respiratory viruse…
DOI: 10.1093/cid/ciae596 -
Immune profiles provide insights into respiratory syncytial virus disease severity in young children
A multi-omics study in 190 children under 2 years with RSV infection and healthy controls, integrating blood transcriptional profiles, immune cell phenotyping, and viral loads to define immune signatures of RSV disease severity and how age shifts these responses, revealing that …
DOI: 10.1126/scitranslmed.aaw0268 -
Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age
This study characterizes RSV-specific maternal antibodies in plasma from hospitalized infants under three months old to assess whether antibody quantity, avidity, neutralization, or epitope-specificity relate to disease severity, concluding no clear antibody signature predicts s…
DOI: 10.1371/journal.pone.0170877 -
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
This review surveys the current RSV vaccine landscape, detailing four main vaccine formats (particle-based, vector-based, subunit, and live-attenuated) and monoclonal antibodies, summarizing clinical trial results, safety profiles, and implications for vaccination strategies in …
DOI: 10.3390/vaccines8040672 -
Turkish pediatricians’ knowledge, attitudes, and awareness of respiratory syncytial virus (RSV) infection and immunization strategies: a cross-sectional study
Turkish pediatricians exhibit substantial gaps in RSV vaccine and nirsevimab knowledge, with frequent non-evidence-based practices (e.g., chest X-rays and nebulized therapies) and limited awareness of maternal vaccination, signaling an urgent need for targeted clinician educatio…
DOI: 10.24953/turkjpediatr.2025.5528 -
Boosting RSV Immunization Uptake in The Netherlands: (Expectant) Mothers and Healthcare Professionals’ Insights on Different Strategies
A mixed-method cross-sectional study in the Netherlands assessing acceptability, drivers, and barriers for RSV prevention through maternal vaccination versus neonatal immunization among (expectant) mothers and healthcare professionals to inform uptake strategies.
DOI: 10.3390/vaccines13101051 -
Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge
This study demonstrates that maternal immunization of baboons with an RSV F nanoparticle vaccine induces high maternal antibodies that cross the placenta, providing neonatal baboons with protection against RSV pulmonary challenge and resulting in milder disease, lower viral load…
DOI: 10.1016/j.vaccine.2019.11.003 -
MATERNAL VACCINATION
Maternal vaccination is a safe and effective public health strategy that protects mothers and infants across multiple vaccines (influenza, COVID-19, RSV, and Tdap), but long-term infant outcomes, population diversity, and uptake hesitancy remain significant challenges.
DOI: 10.58395/zzf7tr35 -
Recent advances in the prevention and treatment of respiratory syncytial virus disease
A comprehensive up-to-date review of respiratory syncytial virus (RSV) prevention and treatment strategies, detailing licensed vaccines, maternal and pediatric options, long-acting monoclonal antibodies, and vaccines/treatments in development, with critical analysis of efficacy,…
DOI: 10.1099/jgv.0.002095 -
Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation
Post hoc MATISSE analysis indicates maternal RSVpreF vaccination at 32–36 weeks gestation reduces severe RSV-associated lower respiratory tract illness in infants up to 6 months and shows a favorable safety profile, aligning with primary trial results.
DOI: 10.57187/4711 -
Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in infants, with most deaths in low- and middle-income countries; next-generation half-life-extended monoclonal antibodies such as nirsevimab show promise for affordable single-dos…
DOI: 10.3390/vaccines9090961 -
Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze
This study investigates the relationship between maternally derived respiratory syncytial virus (RSV) neutralizing antibodies in cord blood and the incidence of RSV hospitalization and recurrent wheeze in infants, finding that while these antibodies protect against hospitalizati…
DOI: 10.1016/j.jaci.2008.10.043 -
Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis
A comprehensive review of respiratory syncytial virus (RSV) prevention strategies emphasizing maternal immunization with RSVPreF and infant monoclonal antibodies (nirsevimab/clesrovimab), their efficacy in reducing severe RSV disease and hospitalization, safety, implementation c…
DOI: 10.2478/abm-2025-0015 -
Complement fixation and neutralization RS antibodies in maternal and neonatal sera
Cord blood RSV complement fixation antibody titres exceed maternal levels, while neutralization titres are similar between maternal and cord sera.
DOI: 10.1017/s0022172400056308 -
US healthcare professionals’ knowledge, attitudes, and practices regarding RSV disease and vaccination in adults during the 2024–2025 RSV season
A cross-sectional survey of 700 US healthcare professionals found that 72.3% were very familiar with RSV disease, but knowledge gaps persisted regarding vaccine indications and ACIP recommendations, and only 36.4% of workplaces stocked RSV vaccines despite 84.1% recommending the…
DOI: 10.1371/journal.pone.0353266 -
234. Safety and Immunogenicity of mRNA-1345, an mRNA-Based RSV Vaccine in Younger and Older Adult Cohorts: Results from a Phase 1, Randomized Clinical Trial
In a phase 1 randomized trial in younger and older adults, Moderna's mRNA-1345 RSV vaccine was well-tolerated and immunogenic, boosting neutralizing and PreF-binding antibodies through month 6 with sustained responses across age groups.
DOI: 10.1093/ofid/ofac492.312 -
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
This cross-sectional study characterizes the first cohort of Italian older adults vaccinated with the adjuvanted RSVPreF3 OA vaccine in Liguria (n=453), detailing their sociodemographic and clinical characteristics, high prevalence of comorbidities, uptake of other vaccines, and…
DOI: 10.3390/medicina61010067 -
A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge
One-dose intranasal PIV5-vectored vaccines expressing RSV F or G confer protection against RSV challenge in cotton rats and African green monkeys, with PIV5/F providing near-complete lung protection and PIV5/G offering substantial protection and boosting neutralizing antibodies …
DOI: 10.1128/jvi.00066-17 -
ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves
A bovine RSV calf model study demonstrates that the chimpanzee adenovirus-vectored vaccine ChAd155-RSV is immunogenic and highly protective against bovine RSV infection–induced disease and lung pathology, with two-dose regimens yielding robust neutralizing antibody responses and…
DOI: 10.1038/s41467-022-33649-3 -
Efficacy of a Novel Nanoparticle RSV Vaccine in Preventing Infection in Older Adults: Phase III Clinical Trial
Nano-RSV, a liposome-encapsulated prefusion F protein nanoparticle RSV vaccine, reduces lab-confirmed RSV LRTI incidence and RSV-related hospitalizations in adults 60+ with a safety profile similar to placebo.
DOI: 10.54963/ti.v9i4.1004 -
DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection
This study compares the immunogenicity of three designer pre-fusion F proteins of respiratory syncytial virus (RSV) vaccines, demonstrating that the DS2 vaccine induces the strongest antibody responses and provides robust protection against RSV infection.
DOI: 10.1038/s41541-024-01059-9 -
Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12–59 months
A phase 1 randomized, observer-blind trial in RSV-seropositive children aged 12–59 months found that the mRNA-1345 RSV vaccine is well tolerated at 15 or 30 μg, elicits robust RSV-A and RSV-B neutralizing and binding antibody responses after a single injection with limited react…
DOI: 10.1080/21645515.2025.2557676 -
Correction: Riccò et al. Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options. Vaccines 2024, 12, 1317
This article is a correction to a previously published RSV vaccine consensus document, clarifying that the corrected Figure 4 does not support differences in vaccine efficacy due to differing endpoints and follow-up, and that the figure is not intended for direct vaccine compari…
DOI: 10.3390/vaccines13080878